Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4386 USD | +6.98% | +4.43% | -79.97% |
Jun. 03 | Aethlon Medical, Inc. Prepares for Potentially Transformative Phase 1 Cancer Treatment Studies | CI |
May. 15 | Top Midday Decliners | MT |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 4.05M |
---|---|---|---|---|---|
Net income 2024 * | -13M | Net income 2025 * | -13M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.08
x | P/E ratio 2025 * |
-0.12
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.66% |
Latest transcript on Aethlon Medical, Inc.
1 day | +6.98% | ||
1 week | +4.43% | ||
Current month | +0.37% | ||
1 month | -68.45% | ||
3 months | -74.65% | ||
6 months | -79.11% | ||
Current year | -79.97% |
Managers | Title | Age | Since |
---|---|---|---|
James Frakes
CEO | Chief Executive Officer | 67 | 08-01-08 |
Lee Arnold
CTO | Chief Tech/Sci/R&D Officer | 64 | - |
Guy Cipriani
COO | Chief Operating Officer | 54 | 18-06-18 |
Members of the board | Title | Age | Since |
---|---|---|---|
James Frakes
CEO | Chief Executive Officer | 67 | 08-01-08 |
Chairman | 88 | 99-03-09 | |
Guy Cipriani
COO | Chief Operating Officer | 54 | 18-06-18 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-05 | 0.4386 | +6.98% | 16,336,935 |
24-06-04 | 0.41 | -10.87% | 1,894,878 |
24-06-03 | 0.46 | +5.26% | 5,206,008 |
24-05-31 | 0.437 | +9.25% | 3,645,934 |
24-05-30 | 0.4 | -4.76% | 1,213,376 |
Delayed Quote Nasdaq, June 05, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-79.97% | 4.05M | |
+8.38% | 220B | |
+15.78% | 198B | |
+31.27% | 112B | |
+4.75% | 66.17B | |
+14.19% | 52.47B | |
+4.70% | 50.77B | |
-3.93% | 38.97B | |
-0.47% | 35.13B | |
+23.96% | 31.32B |
- Stock Market
- Equities
- AEMD Stock